- Johnson & Johnson
- Cougar Biotechnology Inc.
- Janssen R&D Ireland
- Gilead Sciences Inc.
- Bristol-Myers Squibb Co.
- Elan Corp. PLC
- Pfizer Inc.
- Ortho-McNeil-Janssen Pharmaceuticals Inc.
- Janssen Vaccines & Prevention BV
- Eli Lilly & Co.
- Ortho-McNeil Inc.
- Bayer AG
- Grunenthal GMBH
- ViiV Healthcare
- GlaxoSmithKline PLC
- Vertex Pharmaceuticals Inc.
- Medivir AB
- J&J buys Cougar Biotechnology for about $894mm
- Gilead gets global rights to Tibotec's TMC278
- AHP, Elan develop Alzheimer's vaccine; concluded
- J&J signs $1.385bn deal with Elan for Alzheimer's program
- J&J signs influenza deal, buys 18% of Crucell for $443mm
- Ortho-McNeil licenses US rights to Bayer's antithrombotic
- Pfizer and GlaxoSmithKline set up HIV joint venture
- J&J gets rights to Vertex's VX950 for HCV; Janssen buys royalty rights
- Medivir signs hepatitis C deal with Tibotec
- Medivir, Tibotec partner again for HCV inhibitors
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.